# Lightchain

> Lightchain is a VC fund backing Biotechnology, Therapeutics and Health Diagnostics. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 12
- Last investment: Nov 2021
- Lead investor: 33%
- Last updated: Aug 2026

Lightchain is a non-profit organization that specializes in Information technology software & the internet.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Therapeutics | 3 | 25% |
| Health Diagnostics | 3 | 25% |
| Medical | 2 | 17% |
| Health Care | 2 | 17% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 33% |
| Series A | 2 | 17% |
| Series C | 2 | 17% |
| Funding Round | 2 | 17% |
| Series D | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M | Series B | Nov 16, 2021 |  |
| Wugen | Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cellmalignancies. | $172M | Series B | Jul 15, 2021 |  |
| Arch Oncology | At Arch Oncology, they are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. They are committed to advancing antibodies with best-in-class potential.Their next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative toother agents in this class. | $105M | Series C | Apr 27, 2021 |  |
| Arch Oncology | Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses. | $105M | Series C | Apr 27, 2021 |  |
| Mana Therapeutics | Educating Immune Cells, Eliminating Cancer. Our team of scientists, physicians, and advocates are passionate about one thing: harnessing our immune cells to combat cancer - conferring lifelong immunity to the disease. Meet the team charged with immune cell education and cancer elimination. | $35M | Series A | Jan 08, 2021 |  |
| SharpenCX | Sharpen is committed to building software that improves the lives of contact center agents. Its cloud-native platform was built from the ground up free from the anchors of legacy code. With open REST APIs, companies can use the Sharpen platform as the foundation on which to configure solutions to solve their customer service problems.Sharpen hasdeveloped a holistic solution designed to eliminate common inefficiencies that ultimately impact the agent, their quality of life, and their ability to provide a perfect customer experience. By creating a platform that addresses the needs of both IT and the contact center, agents are more prepared and better trained to do their job. The result? Happier, more effective agents creating happy, loyal customers. | $12M |  | Sep 09, 2020 |  |
| C4 Therapeutics | C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causingproteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash.C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber. | $150M | Series B | Jun 16, 2020 |  |
| Adarza BioSystems | Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip.It was founded in 2008 and headquartered in St Louis, Missouri. | $25M | Series D | Feb 04, 2020 |  |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $6.9M | Series A | Oct 02, 2019 |  |
| FinTech Studios | FinTech Studios was founded in 2014 by Jim Tousignant, previously co-founder and President of Multex, a leading online research and financial information platform that went public in 1999 and achieved a market cap of $1.5 billion. FinTech Studios' AI-based apps, big-data analytics and collaboration tools discover and analyze relevantcontent from millions of online sources and proprietary databases with powerful AI-based search technology, providing the most timely and relevant market intelligence and insight for investors, financial professionals and business executives. | $5.1M |  | Sep 16, 2019 |  |

10 of 12 investments shown.

## Co-investors
- [Cultivation Capital](https://shizune.co/investors/profile/cultivation-capital) — VC Fund, 6 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 4 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 3 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 3 deals together
- [3×5 Partners](https://shizune.co/investors/profile/3x5-partners) — VC Fund, 2 deals together
- [3×5 Partners](https://shizune.co/investors/profile/3x5-partners-658c) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Lightchain invest in?

Lightchain invests primarily in Biotechnology, Therapeutics and Health Diagnostics startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lightchain last invest?

The most recent investment recorded for Lightchain closed in Nov 2021. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co